A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin.

ABSTRACT:

Purpose

Physician reported symptomatic late rectal injury occurs in about 5% to 25% of patients treated with radiation therapy for prostate cancer, depending on the treatment technique. Patients, however, report clinically meaningful declines in bowel/rectal function regardless of the technique used. Lovastatin has been shown to protect mice from late radiation injury. This study was designed to determine if lovastatin might reduce the incidence of late rectal injury in patients receiving radiation therapy for prostate cancer.

Materials and methods

Patients with adenocarcinoma of the prostate receiving radiotherapy with curative intent were eligible. A portion of the rectum had to receive at least 60 Gy. Gastrointestinal functioning was assessed using both physician-reported

SUBMITTER: Anscher MS 

PROVIDER: S-EPMC5247423 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature